Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-801
- Development stage
- Discontinued
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
TNX-801 is a live attenuated, synthetic version of the horsepox virus (HPXV) developed as a single-dose vaccine candidate for the prevention of mpox (monkeypox) and smallpox. It is designed to be safer and better tolerated than older vaccinia-based smallpox vaccines while providing durable immunity through robust T-cell responses. Preclinical studies have demonstrated that TNX-801 can induce potent immunity with a single dose, protect non-human primates from lethal mpox challenge, prevent clinical disease and lesions, reduce viral shedding in mucosal tissues (suggesting potential to block transmission), and display significantly greater attenuation compared to traditional vaccinia strains. The vaccine’s formulation allows for easier storage and distribution without ultra-cold chain requirements[1][3][5][7][8][9].
- Brand names
- TNX-801TNX801TNX 801
- Other names
- recombinant horsepox virussynthetic horsepox virus vaccinesmallpox and monkeypox vaccines - Tonix Pharmaceuticals/University of Alberta
Beyond the preview
Go deeper on TNX-801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-801.